INVESTOR RELATIONS
RULE 26 INFORMATION
The following information provided is in accordance with Rule 26.COMPANY INFORMATION
Amarin Corporation plc
The Company is incorporated in England and Wales (Registered number 2353920) and our main country of operation is England.
Our registered office is located at 110 Cannon Street, London EC4N 6AR, England. Our principal executive offices are located at 7 Curzon Street, London W1J 5HG, England.
Description of Business
Amarin is committed to improving the lives of patients suffering from central nervous system and cardiovascular diseases. Our goal is to be a leader in the research, development and commercialization of novel drugs that address unmet patient needs.
Amarin currently has a broad neuroscience development pipeline comprising four key clinical development programs plus several pre-clinical opportunities. Clinical programs include Miraxion for Huntington's disease, EN101 for Myasthenia Gravis, an oral formulation of apomorphine for treating advanced Parkinson's disease patients experiencing frequent “off” episodes; a treatment for memory and cognition; a nasal formulation of lorazepam for treating emergency epilepsy seizures in the out-patient setting; and brain targeted delivery of levodopa for Parkinson’s disease which utilizes Amarin’s targeted transport lipid technology.
Amarin has initiated a cardiovascular development program to capitalize on the known therapeutic benefits of unsaturated fatty acids in cardiovascular disease. Amarin plans to utilize its extensive know-how and experience in lipid science to develop a series of products targeting the vascular system, endothelial dysfunction and vascular re-modeling. Amarin intends to commence a series of clinical trials with AMR 101 (97% pure EPA) in dyslipidemia, the first of which will commence by the end of this year. In addition, Amarin intends to commence investigation of new compounds from its existing development portfolio for the treatment of metabolic syndrome and dyslipidemia.
Amarin also has a platform messenger RNA (MRNA) silencing technology which targets the cholinergic pathway. In addition a proprietary lipid-based technology platform for the targeted transport of molecules through the liver and/or to the brain that can be leveraged in a wide range of disease applications for its own product pipeline or with potential partners.
Company Announcements
Click here for full list
Most Recent Annual and Interim Report
Click here for full list
Most Recent Admission Documents
AIM Schedule One
IEX Schedule One
Appendix to Schedule One
PRINCIPAL ADVISORS
Nominated Advisor, IEX Advisor and Broker:
Davy, Davy House, 49 Dawson Street, Dublin 2, Ireland
UK Solicitors to the Company
Kirkpatrick & Lockhart Nicholson Graham LLP, 110 Cannon Street, London EC4N 6AR, UK.
Irish Solicitors to the Company:
Matheson Ormsby Prentice Solicitors, 70 Sir John Rogerson's Quay, Dublin 2, Ireland
US Solicitors to the Company:
Cahill Gordon & Reindel LLP, Augustine House, 6A Austin Friars, London EC2N 2HA, England.
Reporting Accountants and Auditors:
PricewaterhouseCoopers, One Spencer Dock, North Wall Quay, Dublin 1, Ireland.
Registrars and Transfer Agent:
Lloyds TSB Registrars, The Causeway, Worthing, West Sussex BN99 6DA, UK.
Principal Bankers:
Lloyds TSB Corporate, PO Box 18436, 1 st Floor, 39 Threadneedle Street, London EC2R 8PT, UK.
SECURITIES
Trading Platforms
Alternative Investment Market (‘AMRN’)
Irish Enterprise Exchange (‘H2E’)
NASDAQ Capital Market (‘AMRN’)
Current Ordinary Shares in Issue
14,003,237 ordinary shares of £0.50 each (20,079 of these shares are held in treasury)
Details, if any, of restriction on the transfer of securities:
There are no restrictions on the transfer of securities
Substantial Shareholders
|
Number of ordinary shares |
% of issued share capital |
|
| Amarin Investment Holding Limited (1) |
1,072,906 |
7.66% |
| Medica Funds |
1,007,796 |
7.20% |
| Dr. Simon Kukes |
951,608 |
6.80% |
| Sunninghill Limited (2) |
944,016 |
6.74% |
- Amarin Investment Holding Limited is an entity controlled by our Chairman, Mr. Thomas Lynch
- Sunninghill Limited is an entity controlled by one of our non-executive directors, Dr. John Climax
In accordance with the AIM and IEX Rules (Rule 26), in so far as the Company is aware, the percentage of the Company’s issued share capital that is not in public hands is 22.31%, This percentage comprises the total holdings of the directors and officers in the Company including those of Mr. Thomas Lynch, Dr. Simon Kukes and Dr. John Climax outlined above.
BOARD OF DIRECTORS
MEMORANDUM AND ARTICLES OF ASSOCIATION
LEAD INDEPENDENT DIRECTOR CHARTER
Note
All the above information is correct as of 26 February 2008.
